148 related articles for article (PubMed ID: 15892503)
21. Current management of diabetes mellitus and future directions in care.
Chatterjee S; Davies MJ
Postgrad Med J; 2015 Nov; 91(1081):612-21. PubMed ID: 26453594
[TBL] [Abstract][Full Text] [Related]
22. Influence of glycemic control on the development of diabetic cardiovascular and kidney disease.
Saha SA; Tuttle KR
Cardiol Clin; 2010 Aug; 28(3):497-516. PubMed ID: 20621253
[TBL] [Abstract][Full Text] [Related]
23. [A therapeutic option for type-2 diabetes. The incretion hormone GLP-1].
Göke B; Hoppe B; Konrad A; Schirra J
Pharm Unserer Zeit; 2002; 31(3):294-9. PubMed ID: 12071126
[No Abstract] [Full Text] [Related]
24. Oral pharmacologic management of type 2 diabetes.
Riddle MC
Am Fam Physician; 1999 Dec; 60(9):2613-20. PubMed ID: 10605995
[TBL] [Abstract][Full Text] [Related]
25. Oral combination therapy in primary care.
Kalra S; Gupta Y
J Pak Med Assoc; 2015 May; 65(5):574-5. PubMed ID: 26028398
[TBL] [Abstract][Full Text] [Related]
26. Diabetes and diabetes medications.
Turkoski BB
Orthop Nurs; 2006; 25(3):227-31. PubMed ID: 16735857
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.
Nauck M
Diabet Med; 1996 Sep; 13(9 Suppl 5):S39-43. PubMed ID: 8894470
[TBL] [Abstract][Full Text] [Related]
28. [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
Matthes J; Faust M
Dtsch Med Wochenschr; 2008 Oct; 133(43):2233-7. PubMed ID: 18924057
[No Abstract] [Full Text] [Related]
29. Theratechnologies expands peptide portfolio in endocrinology.
Walczak IM
Diabetes Technol Ther; 2002; 4(5):734. PubMed ID: 12458565
[No Abstract] [Full Text] [Related]
30. Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.
Foley JE; Ligueros-Saylan M; He YL; Holst JJ; Deacon CF; Dunning BE; Leone-Jones A; Yu T; Kelley DE
Horm Metab Res; 2008 Oct; 40(10):727-30. PubMed ID: 18597213
[No Abstract] [Full Text] [Related]
31. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
32. Which oral drug is right for your type 2 diabetes? New thinking on oral drug combinations that can provide better glycemic control.
Health News; 2005 Feb; 11(2):10-1. PubMed ID: 15732153
[No Abstract] [Full Text] [Related]
33. [Selection of oral antidiabetic drugs].
Iwamoto Y
Nihon Rinsho; 2005 Feb; 63 Suppl 2():428-32. PubMed ID: 15779417
[No Abstract] [Full Text] [Related]
34. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
Göke R; Gruenberger JB; Bader G; Dworak M
Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
[TBL] [Abstract][Full Text] [Related]
35. Molecule of the month. Vildagilptin.
Drug News Perspect; 2006 May; 19(4):228. PubMed ID: 16823497
[No Abstract] [Full Text] [Related]
36. Insulin and oral hypoglycemic agents.
Price MJ
Nurs Clin North Am; 1983 Dec; 18(4):687-706. PubMed ID: 6359069
[No Abstract] [Full Text] [Related]
37. Pharmacologic management of diabetes mellitus.
Mozersky RP
J Am Osteopath Assoc; 1999 Dec; 99(12 Suppl):S15-9. PubMed ID: 10659525
[TBL] [Abstract][Full Text] [Related]
38. Diabetes medications update.
Childs BP
Kans Nurse; 2004 May; 79(5):4-6. PubMed ID: 15216607
[No Abstract] [Full Text] [Related]
39. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
Nauck MA
Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
[TBL] [Abstract][Full Text] [Related]
40. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
Dupre J
Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
